Javad Nazarian

List of Publications by Year
in descending order

144 papers	4,407 citations	117625 34 h-index	114465 63 g-index
151 all docs	151 docs citations	151 times ranked	6111 citing authors

#	Article	IF	Citations
1	Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nature Genetics, 2014, 46, 451-456.	21.4	525
2	Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nature Medicine, 2015, 21, 555-559.	30.7	473
3	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. Journal of Clinical Oncology, 2018, 36, 1963-1972.	1.6	250
4	Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nature Communications, 2016, 7, 11185.	12.8	197
5	Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer. Cell, 2020, 183, 1962-1985.e31.	28.9	177
6	Preclinical Evaluation of Radiation and Perifosine in a Genetically and Histologically Accurate Model of Brainstem Glioma. Cancer Research, 2010, 70, 2548-2557.	0.9	149
7	Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy. Journal of Cell Biology, 2014, 207, 139-158.	5.2	130
8	Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy. Clinical Cancer Research, 2018, 24, 5850-5859.	7.0	118
9	Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State. Molecular Cell, 2019, 76, 965-980.e12.	9.7	110
10	Advances in the proteomic investigation of the cell secretome. Expert Review of Proteomics, 2012, 9, 337-345.	3.0	109
11	Comparative multidimensional molecular analyses of pediatric diffuse intrinsic pontine glioma reveals distinct molecular subtypes. Acta Neuropathologica, 2014, 127, 881-895.	7.7	91
12	Direct analysis of lipids and small metabolites in mouse brain tissue by AP IR-MALDI and reactive LAESI mass spectrometry. Analyst, The, 2010, 135, 751.	3.5	90
13	ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis. Nature Communications, 2019, 10, 1023.	12.8	87
14	Molecular Imaging of Biological Samples on Nanophotonic Laser Desorption Ionization Platforms. Angewandte Chemie - International Edition, 2016, 55, 4482-4486.	13.8	86
15	A pilot precision medicine trial for children with diffuse intrinsic pontine gliomaâ€"PNOC003: A report from the Pacific Pediatric Neuroâ€Oncology Consortium. International Journal of Cancer, 2019, 145, 1889-1901.	5.1	84
16	Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. Journal of Clinical Investigation, 2020, 130, 6325-6337.	8.2	70
17	Insights into pediatric diffuse intrinsic pontine glioma through proteomic analysis of cerebrospinal fluid. Neuro-Oncology, 2012, 14, 547-560.	1.2	66
18	Human pontine glioma cells can induce murine tumors. Acta Neuropathologica, 2014, 127, 897-909.	7.7	63

#	Article	IF	Citations
19	Disrupting NOTCH Slows Diffuse Intrinsic Pontine Glioma Growth, Enhances Radiation Sensitivity, and Shows Combinatorial Efficacy With Bromodomain Inhibition. Journal of Neuropathology and Experimental Neurology, 2015, 74, 778-790.	1.7	61
20	The Pediatric Cell Atlas: Defining the Growth Phase of Human Development at Single-Cell Resolution. Developmental Cell, 2019, 49, 10-29.	7.0	57
21	Morphologic Characteristics and Immunohistochemical Profile of Diffuse Intrinsic Pontine Gliomas. American Journal of Surgical Pathology, 2013, 37, 1357-1364.	3.7	55
22	PPM1D mutations silence NAPRT geneÂexpression and confer NAMPT inhibitor sensitivity in glioma. Nature Communications, 2019, 10, 3790.	12.8	54
23	Ambient molecular imaging by laser ablation electrospray ionization mass spectrometry with ion mobility separation. International Journal of Mass Spectrometry, 2015, 377, 681-689.	1.5	53
24	The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma. Cancer Letters, 2017, 400, 110-116.	7.2	52
25	Genetic and Clinical Heterogeneity in eIF2B-Related Disorder. Journal of Child Neurology, 2008, 23, 205-215.	1.4	46
26	The Role of NG2 Proteoglycan in Glioma. Translational Oncology, 2016, 9, 57-63.	3.7	43
27	Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naÃ¯ve diffuse midline glioma models. Neuro-Oncology, 2021, 23, 376-386.	1.2	43
28	InÂvitro analysis of metabolites from the untreated tissue of Torpedo californica electric organ by mid-infrared laser ablation electrospray ionization mass spectrometry. Metabolomics, 2009, 5, 263-276.	3.0	42
29	Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma. Neuro-Oncology, 2020, 22, 1302-1314.	1.2	42
30	A standardized autopsy procurement allows for the comprehensive study of DIPG biology. Oncotarget, 2015, 6, 12740-12747.	1.8	41
31	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821.	1.6	40
32	Intracellular expression profiling by laser capture microdissection: three novel components of the neuromuscular junction. Physiological Genomics, 2005, 21, 70-80.	2.3	38
33	Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2021, 27, 1766-1777.	7.0	38
34	Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas. Neuro-Oncology, 2022, 24, 1438-1451.	1.2	36
35	Increased 5-hydroxymethylcytosine and decreased 5-methylcytosine are indicators of global epigenetic dysregulation in diffuse intrinsic pontine glioma. Acta Neuropathologica Communications, 2014, 2, 59.	5.2	35
36	Clinicopathology of diffuse intrinsic pontine glioma and its redefined genomic and epigenomic landscape. Cancer Genetics, 2015, 208, 367-373.	0.4	35

#	Article	IF	Citations
37	Manganese-containing Prussian blue nanoparticles for imaging of pediatric brain tumors. International Journal of Nanomedicine, 2014, 9, 2581.	6.7	33
38	Medulloblastoma rendered susceptible to NK-cell attack by TGFÎ² neutralization. Journal of Translational Medicine, 2019, 17, 321.	4.4	32
39	Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR. Scientific Reports, 2021, 11, 5098.	3.3	31
40	Mechanisms of imipridones in targeting mitochondrial metabolism in cancer cells. Neuro-Oncology, 2021, 23, 542-556.	1.2	30
41	The emerging role of NG2 in pediatric diffuse intrinsic pontine glioma. Oncotarget, 2015, 6, 12141-12155.	1.8	30
42	Pediatric high-grade glioma resources from the Childrenâ€™s Brain Tumor Tissue Consortium. Neuro-Oncology, 2020, 22, 163-165.	1.2	29
43	Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas. Science Translational Medicine, 2021, 13, eabc0497.	12.4	29
44	Simultaneous Detection of Nonpolar and Polar Compounds by Heat-Assisted Laser Ablation Electrospray Ionization Mass Spectrometry. Analytical Chemistry, 2013, 85, 177-184.	6.5	27
45	SLC5A8 Gene, A Transporter of Butyrate: A Gut Flora Metabolite, Is Frequently Methylated in African American Colon Adenomas. PLoS ONE, 2011, 6, e20216.	2.5	27
46	Pediatric hemispheric high-grade glioma: targeting the future. Cancer and Metastasis Reviews, 2020, 39, 245-260.	5.9	26
47	Liquid biopsy for pediatric central nervous system tumors. Npj Precision Oncology, 2018, 2, 29.	5.4	24
48	Î”Np73/ETS2 complex drives glioblastoma pathogenesisâ€” targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma. Neuro-Oncology, 2020, 22, 345-356.	1.2	20
49	The proteome survey of an electricity-generating organ(Torpedo californicaelectric organ). Proteomics, 2007, 7, 617-627.	2.2	19
50	Splicing is an alternate oncogenic pathway activation mechanism in glioma. Nature Communications, 2022, 13, 588.	12.8	17
51	Molecular Imaging of Biological Samples on Nanophotonic Laser Desorption Ionization Platforms. Angewandte Chemie, 2016, 128, 4558-4562.	2.0	16
52	Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas. Cancer Research, 2019, 79, 4026-4041.	0.9	16
53	Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma. Journal of Experimental and Clinical Cancer Research, 2020, 39, 261.	8.6	16
54	Advances in Targeted Therapies for Pediatric Brain Tumors. Current Treatment Options in Neurology, 2020, 22, 1.	1.8	16

#	Article	IF	Citations
55	Protein profiling of formalin fixed paraffin embedded tissue: Identification of potential biomarkers for pediatric brainstem glioma. Proteomics - Clinical Applications, 2008, 2, 915-924.	1.6	15
56	Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience. Medicines (Basel, Switzerland), 2020, 7, 29.	1.4	15
57	Molecular and functional analysis of anchorage independent, treatment-evasive neuroblastoma tumorspheres with enhanced malignant properties: A possible explanation for radio-therapy resistance. PLoS ONE, 2018, 13, e0189711.	2.5	12
58	REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature. Oncotarget, 2018, 9, 5233-5250.	1.8	12
59	Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma. Neuro-Oncology Advances, 2021, 3, vdab169.	0.7	11
60	Characteristics of patients â‰¥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. Neuro-Oncology, 2022, 24, 141-152.	1.2	9
61	Vamorolone, a dissociative steroidal compound, reduces pro-inflammatory cytokine expression in glioma cells and increases activity and survival in a murine model of cortical tumor. Oncotarget, 2017, 8, 9366-9374.	1.8	9
62	Harmonization of postmortem donations for pediatric brain tumors and molecular characterization of diffuse midline gliomas. Scientific Reports, 2020, 10, 10954.	3.3	7
63	Histological and molecular analysis of a progressive diffuse intrinsic pontine glioma and synchronous metastatic lesions: a case report. Oncotarget, 0, 7, 42837-42842.	1.8	7
64	Evolution and comparative genomics of subcellular specializations: EST sequencing of Torpedo electric organ. Marine Genomics, 2011, 4, 33-40.	1.1	6
65	Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids. Journal of Visualized Experiments, 2019, , .	0.3	5
66	Differential Expression of Wilmsâ€™ Tumor Protein in Diffuse Intrinsic Pontine Glioma. Journal of Neuropathology and Experimental Neurology, 2019, 78, 380-388.	1.7	5
67	GENE-12. THE CHILDRENâ€™S BRAIN TUMOR TISSUE CONSORTIUM (CBTTC) INFRASTRUCTURE FACILITATES COLLABORATIVE RESEARCH IN PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS. Neuro-Oncology, 2017, 19, iv20-iv21.	1.2	3
68	GENE-15. CAVATICA- AÂPEDIATRIC GENOMIC CLOUD EMPOWERING DATA DISCOVERY THROUGH THE PEDIATRIC BRAIN TUMOR ATLAS. Neuro-Oncology, 2017, 19, iv21-iv21.	1.2	3
69	DIPG-76. PNOC-003: PRECISION MEDICINE TRIAL FOR CHILDREN WITH DIFFUSES INTRINSIC PONTINE GLIOMA: PRELIMINARY EXPERIENCE WITH MULTI-AGENT PERSONALIZED THERAPY RECOMMENDATIONS. Neuro-Oncology, 2018, 20, i64-i64.	1.2	2
70	Somatic Mosaicism of IDH1 R132H Predisposes to Anaplastic Astrocytoma: A Case of Two Siblings. Frontiers in Oncology, 2019, 9, 1507.	2.8	2
71	HGG-32. ONC201 AND ONC206 TARGET TUMOR CELL METABOLISM IN PEDIATRIC DIFFUSE MIDLINE GLIOMA PRECLINICAL MODELS. Neuro-Oncology, 2021, 23, i23-i24.	1.2	2
72	DDRE-21. PNOC015: PHASE 1 STUDY OF MTX110 DELIVERED BY CONVECTION ENHANCED DELIVERY (CED) IN CHILDREN WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) PREVIOUSLY TREATED WITH RADIATION THERAPY. Neuro-Oncology, 2020, 22, ii66-ii66.	1.2	2

#	Article	IF	Citations
73	HG-75CLINICAL, RADIOLOGICAL, AND HISTO-GENETIC CHARACTERISTICS OF LONG-TERM SURVIVORS OF DIFFUSE INTRINSIC PONTINE GLIOMA: A COLLABORATIVE REPORT FROM THE INTERNATIONAL AND SIOP-E DIPG REGISTRIES. Neuro-Oncology, 2016, 18, iii65.3-iii66.	1.2	1
74	DIPG-40. PNOC-003: PRECISION MEDICINE TRIAL FOR CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2017, 19, iv14-iv14.	1.2	1
75	GENE-18. USE OF PRIMARY TEETH AND AÂTOOTH BRUSH AS SOURCES OF DNA IN AN ANAPLASTIC ASTROCYTOMA CASE. Neuro-Oncology, 2017, 19, vi96-vi96.	1.2	1
76	PDTM-25. GENETIC SUSCEPTIBILITY AND EVOLUTION OF PEDIATRIC IDH-MUTANT INFILTRATING ASTROCYTOMAS. Neuro-Oncology, 2017, 19, vi195-vi195.	1.2	1
77	TMIC-25. TUMOR MIGRATION AND ROLE OF MICROENVIRONMENT IN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2017, 19, vi248-vi248.	1.2	1
78	DIPG-69. CHARACTERISTICS OF PATIENTS â‰¥ 10 YEARS OF AGE WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. Neuro-Oncology, 2018, 20, i63-i63.	1.2	1
79	DIPG-51. BLACKFYNN: A SECURE, CLOUD-BASED PLATFORM FOR SHARING AND ANALYZING RESEARCH READY DATA FOR PEDIATRIC CNS CANCERS. Neuro-Oncology, 2018, 20, i59-i59.	1.2	1
80	EPID-14. GABRIELLA MILLER KIDS FIRST DATA RESOURCE CENTER: COLLABORATIVE PLATFORMS FOR ACCELERATING RESEARCH IN PEDIATRIC CANCERS & STRUCTURAL BIRTH DEFECTS. Neuro-Oncology, 2020, 22, iii321-iii321.	1.2	1
81	DIPG-09. Diffuse Midline Glioma-Adaptive Combinatory Trial (DMG-ACT): A biology-driven platform trial in pediatric and young adult patients with diffuse midline glioma. Neuro-Oncology, 2022, 24, i19-i19.	1.2	1
82	Diffuse Intrinsic Pontine Glioma: A Therapeutic Challenge. , 0, , .		0
83	HG-62NEEDS AND MEANS OF POSTMORTEM BRAIN TUMOR DONATION AND COORDINATION: ONE CENTER'S EXPERIENCE. Neuro-Oncology, 2016, 18, iii62.1-iii62.	1.2	0
84	HG-89DEVELOPMENT OF A CHILDHOOD CENTRAL NERVOUS SYSTEM BIOREPOSITORY. Neuro-Oncology, 2016, 18, iii69.1-iii69.	1.2	0
85	HG-76SPATIAL AND TEMPORAL HOMOGENEITY OF DRIVER MUTATIONS IN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2016, 18, iii66.1-iii66.	1.2	0
86	MB-44SUBGROUP-SPECIFIC QUANTITATIVE PROTEOMIC ANALYSIS OF MEDULLOBLASTOMA. Neuro-Oncology, 2016, 18, iii106.4-iii106.	1.2	0
87	HG-63NOVEL DISSOCIATIVE STEROIDS FOR TREATMENT OF EDEMA IN CHILDHOOD INTRACRANIAL BRAIN TUMORS. Neuro-Oncology, 2016, 18, iii62.2-iii62.	1.2	0
88	HG-115PRECISION MEDICINE APPROACH FOR CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2016, 18, iii75.1-iii75.	1.2	0
89	HG-91TOPOGRAPHIC HISTOLOGICAL AND MOLECULAR STUDIES OF DIFFUSE INTRINSIC PONTINE GLIOMA TREATED WITH CONVECTION ENHANCED DELIVERY. Neuro-Oncology, 2016, 18, iii69.3-iii69.	1.2	0
90	HG-24GLUCOCORTICOID-MEDIATED EPIGENOMIC REVERSAL IN DIFFUSE INTRINSIC PONTINE GLIOMAS. Neuro-Oncology, 2016, 18, iii52.4-iii52.	1.2	0

#	Article	IF	Citations
91	HG-61MOLECULAR CHARACTERIZATION OFIN VIVOANDIN VITROMODELS OF DIPG. Neuro-Oncology, 2016, 18, iii61.4-iii62.	1.2	0
92	HG-74DEVELOPMENT OF ROBUST IN VITRO AND IN VIVO PRE-CLINICAL MODELS FOR DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2016, 18, iii65.2-iii65.	1.2	0
93	PCM-05AUTOPSY-DERIVED ORTHOTOPIC XENOGRAFT MOUSE MODELS OF TERMINAL PEDIATRIC BRAIN TUMORS. Neuro-Oncology, 2016, 18, iii140.1-iii140.	1.2	0
94	HG-64DEVELOPMENT OF IN VIVO DRUG AND GENE DELIVERY SYSTEMS TO BRAIN TUMOR USING LIPOSOMAL NANOCARRIERS. Neuro-Oncology, 2016, 18, iii62.3-iii62.	1.2	0
95	Titelbild: Molecular Imaging of Biological Samples on Nanophotonic Laser Desorption Ionization Platforms (Angew. Chem. 14/2016). Angewandte Chemie, 2016, 128, 4443-4443.	2.0	0
96	DIPG-12. OPTIMIZATION OF OSMOTIC PUMP IMPLANTATION FOR DELIVERY OF THERAPEUTICS VIA CONVECTION ENHANCED DELIVERY IN PRECLINICAL MODELS OF DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2017, 19, iv7-iv7.	1.2	0
97	DIPG-39. LIQUID BIOPSY FOR MONITORING OF TUMOR RESPONSE IN CHILDREN WITH MIDLINE GLIOMAS. Neuro-Oncology, 2017, 19, iv13-iv14.	1.2	0
98	GENE-43. LIQUID BIOPSY FOR MONITORING OF TUMOR RESPONSE IN CHILDREN WITH DIFFUSE MIDLINE GLIOMA. Neuro-Oncology, 2017, 19, vi101-vi102.	1.2	0
99	MEDU-10. THE PROTEO(EPI)GENOMICS OF MEDULLOBLASTOMA. Neuro-Oncology, 2017, 19, iv39-iv39.	1.2	0
100	SCDT-30. SURGICAL IMPLANTATION OF AN OSMOTIC PUMP FOR CONVECTION ENHANCED DELIVERY INTO DIPG XENOGRAFT MURINE MODELS. Neuro-Oncology, 2017, 19, vi271-vi271.	1.2	0
101	DIPG-53. COMPREHENSIVE CLINICAL AND MOLECULAR ANALYSIS OF PEDIATRIC THALAMIC GLIOMA. Neuro-Oncology, 2018, 20, i59-i60.	1.2	0
102	DIPG-64. REST MODULATES NEOVASCULATURE VIA REGULATION OF GREMLIN EXPRESSION IN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2018, 20, i62-i62.	1.2	0
103	TBIO-29. PedcBioPortal, A CANCER DATA VISUALIZATION TOOL FOR INTEGRATIVE PEDIATRIC CANCER ANALYSES. Neuro-Oncology, 2018, 20, i186-i186.	1.2	0
104	HGG-37. DETECTION OF IDH1 R132H MOSAICISM IN ANAPLASTIC ASTROCYTOMA PATIENTS. Neuro-Oncology, 2018, 20, i97-i97.	1.2	0
105	PDTM-07. DETECTION OF IDH1 R132H MOSAICISM IN ANAPLASTIC ASTROCYTOMA PATIENTS. Neuro-Oncology, 2018, 20, vi205-vi205.	1.2	0
106	HGG-38. DEVELOPMENT AND COMPREHENSIVE CHARACTERIZATION AND UTILIZATION OF PRECLINICAL MODELS OF PEDIATRIC HIGH GRADE GLIOMAS. Neuro-Oncology, 2018, 20, i97-i97.	1.2	0
107	TBIO-27. GABRIELLA MILLER KIDS FIRST DATA RESOURCE CENTER ADVANCING GENETIC RESEARCH IN CHILDHOOD CANCER AND STRUCTURAL BIRTH DEFECTS THROUGH LARGE SCALE INTEGRATED DATA-DRIVEN DISCOVERY AND CLOUD-BASED PLATFORMS FOR COLLABORATIVE ANALYSIS. Neuro-Oncology, 2018, 20, i186-i186.	1.2	0
108	TBIO-28. DISEASEXPRESS, A CANCER DATA ANALYTICS AND VISUALIZATION TOOL FOR IDENTIFYING IMMUNOTHERAPEUTIC TARGETS IN PEDIATRIC BRAIN TUMORS AND OTHER CANCERS. Neuro-Oncology, 2018, 20, i186-i186.	1.2	0

#	Article	IF	Citations
109	DIPG-58. SUBTYPE-SPECIFIC OVEREXPRESSION OF WILMSâ€™ TUMOR PROTEIN IN PEDIATRIC MIDLINE HIGH GRADE GLIOMAS. Neuro-Oncology, 2018, 20, i60-i61.	1.2	0
110	PDTM-15. IDENTIFICATION AND CHARACTERIZATION OF WILMSâ€™ TUMOR PROTEIN IN PEDIATRIC MIDLINE GLIOMAS. Neuro-Oncology, 2018, 20, vi206-vi207.	1.2	0
111	DIPG-32. CLINICALLY RELEVANT AND MINIMALLY INVASIVE TUMOR SURVEILLANCE IN PEDIATRIC GLIOMAS USING LIQUID BIOME. Neuro-Oncology, 2018, 20, i55-i55.	1.2	0
112	DIPG-31. TUMOR SURVEILLANCE USING LIQUID BIOME IN PEDIATRIC HIGH GRADE GLIOMAS. Neuro-Oncology, 2018, 20, i55-i55.	1.2	0
113	DIPG-52. ACTIVE CHROMATIN IN H3K27M DIPG REVEALS DISTINCT EPIGENETIC SUBTYPES AND SUBTYPE-SPECIFIC MECHANISMS OF PATHOGENESIS. Neuro-Oncology, 2018, 20, i59-i59.	1.2	0
114	DIPG-50. CHROMATIN IMMUNOPRECIPITATION OF DIFFUSE INTRINSIC PONTINE GLIOMA TUMOR TISSUE IS FEASIBLE AND SHOW DIFFERENT ENRICHMENT COMPARED TO PRIMARY CELL LINE. Neuro-Oncology, 2018, 20, i59-i59.	1.2	0
115	DIPG-70. CLINICAL, RADIOLOGICAL, PATHOLOGICAL AND MOLECULAR CHARACTERISTICS OF CHILDREN < 3 YEARS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG): A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. Neuro-Oncology, 2018, 20, i63-i63.	1.2	0
116	TMOD-19. GABRIELLA MILLER KIDS FIRST DATA RESOURCE CENTER: LARGE-SCALE HARMONIZED CLINICAL AND GENOMIC DATA PLATFORM TO SUPPORT CHILDHOOD CANCER AND STRUCTURAL BIRTH DEFECT RESEARCH. Neuro-Oncology, 2019, 21, ii125-ii125.	1.2	0
117	DIPG-30. ISOFORM SPECIFIC OVEREXPRESSION OF WILMSâ€™ TUMOR PROTEIN IN DIFFUSE INTRINSIC PONTINE GLIOMAS. Neuro-Oncology, 2019, 21, ii75-ii75.	1.2	0
118	DIPG-32. COMBINATION OF ChIP-SEQ AND RNA-SEQ ANALYSIS FOR TARGET DISCOVERY REVEAL PROMISING CANDIDATES FOR VALIDATION. Neuro-Oncology, 2019, 21, ii75-ii76.	1.2	0
119	DIPG-35. OPEN DIPG INITIATIVE: A PLATFORM FOR ACCELERATING DISCOVERY THROUGH DATA ACCESS, CONSOLIDATION AND HARMONIZATION. Neuro-Oncology, 2019, 21, ii76-ii76.	1.2	0
120	DIPG-15. PNOC-003: CLINICAL IMPACT OF A PRECISION MEDICINE STRATEGY FOR CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2019, 21, ii71-ii71.	1.2	0
121	TMOD-20. THE PEDIATRIC BRAIN TUMOR ATLAS: AN INITIATIVE BY THE CHILDRENâ€™S BRAIN TUMOR TISSUE CONSORTIUM AND PACIFIC PEDIATRIC NEUROONCOLOGY CONSORTIUM. Neuro-Oncology, 2019, 21, ii125-ii125.	1.2	0
122	DIPG-26. ACVR1 R206H COOPERATES WITH H3.1K27M IN PROMOTING DIFFUSE INTRINSIC PONTINE GLIOMA PATHOGENESIS. Neuro-Oncology, 2019, 21, ii74-ii74.	1.2	0
123	DIPG-33. HARMONIZATION AND CHARACTERIZATION OF POSTMORTEM DONATIONS FOR PEDIATRIC BRAIN TUMORS. Neuro-Oncology, 2019, 21, ii76-ii76.	1.2	0
124	DIPG-34. PRECLINICAL PRECISION TESTING OF PNOC003 BIOPSY DERIVED MODELS OF DIPG. Neuro-Oncology, 2019, 21, ii76-ii76.	1.2	0
125	GENE-18. PAN-OMIC ANALYSIS OF DIFFUSE INTRINSIC PONTINE GLIOMA FROM CHILDREN ENROLLED IN THE PNOC003 PRECISION MEDICINE TRIAL IDENTIFIES OPPORTUNITIES AND CHALLENGES IN CLINICAL IMPLEMENTATION OF A MULTI-OMICS SEQUENCING APPROACH. Neuro-Oncology, 2019, 21, ii85-ii85.	1.2	0
126	HGG-24. COMPREHENSIVE GENOMIC ANALYSIS OF PEDIATRIC GLIOMAS UNCOVERS NOVEL MUTATIONS IN HISTONE-ENCODING GENES. Neuro-Oncology, 2019, 21, ii91-ii92.	1.2	0

#	Article	IF	Citations
127	GENE-20. MULTI-GENE MUTATION PROFILING OF PEDIATRIC MIDLINE GLIOMAS USING PATIENT LIQUID BIOPSY. Neuro-Oncology, 2019, 21, ii85-ii85.	1.2	0
128	Profiling 523 cancer associated genes in circulating tumor DNA of children with CNS tumors.. Journal of Clinical Oncology, 2021, 39, 3023-3023.	1.6	0
129	HGG-23. IN VITRO AND IN VIVO PRECLINICAL DRUG SCREENING OF PROMISING THERAPEUTICS FOR DIFFUSE MIDLINE GLIOMA (DMG). Neuro-Oncology, 2021, 23, i21-i22.	1.2	0
130	OMIC-09. MAPPING THE HISTONE MUTATIONAL LANDSCAPE ACROSS ADULT AND PEDIATRIC CANCER GENOMES UNCOVERS NOVEL SOMATIC MUTATIONS IN PEDIATRIC HIGH-GRADE GLIOMAS. Neuro-Oncology, 2021, 23, i39-i39.	1.2	0
131	An unexpected disease course for a patient with diffuse midline glioma. Pediatric Blood and Cancer, 2021, 68, e29205.	1.5	0
132	Biologic Computing. , 2008, , 259-XXI.		0
133	DIPG-39. NOVEL PROTEOMIC ANALYSIS REVEALS EPIGENETIC THERAPEUTIC TARGETS IN PEDIATRIC GLIOMA. Neuro-Oncology, 2020, 22, iii294-iii294.	1.2	0
134	TAMI-40. PEDIATRIC H3K27M MUTANT GLIOMAS UNDERGO METABOLIC REPROGRAMMING THAT CAN BE LEVERAGED FOR NON-INVASIVE METABOLIC IMAGING. Neuro-Oncology, 2021, 23, vi206-vi207.	1.2	0
135	EXTH-67. PHARMACOLOGIC INHIBITION OF LYSINE SPECIFIC DEMETHYLASE-1 (LSD1) AS AN ADJUVANT IMMUNE-SENSITIZATION STRATEGY IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). Neuro-Oncology, 2020, 22, ii102-ii102.	1.2	0
136	DDRE-03. INTERNATIONAL PRECLINICAL DRUG DISCOVERY AND BIOMARKER PROGRAM INFORMING AN ADOPTIVE COMBINATORIAL TRIAL FOR DIFFUSE MIDLINE GLIOMAS. Neuro-Oncology, 2020, 22, ii61-ii62.	1.2	0
137	CTNI-17. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA. Neuro-Oncology, 2020, 22, ii45-ii46.	1.2	0
138	DDRE-10. IMMUNE PROFILES ASSOCIATE WITH OUTCOMES IN HLA-A*02:01+, H3.3K27M+ PATIENTS WITH DIFFUSE MIDLINE GLIOMAS TREATED WITH H3.3K27M PEPTIDE VACCINE COMBINED WITH POLY-ICLC: A PNOC REPORT. Neuro-Oncology, 2020, 22, ii63-ii63.	1.2	0
139	NFB-20. Pre-clinical models of Mismatch Repair Deficient Gliomas. Neuro-Oncology, 2022, 24, i132-i132.	1.2	0
140	DIPG-48. MRI volumetric and machine learning based analyses predict survival outcome in pediatric diffuse midline glioma. Neuro-Oncology, 2022, 24, i29-i29.	1.2	0
141	IMG-16. Non-invasive metabolic imaging of response to therapy in diffuse midline gliomas. Neuro-Oncology, 2022, 24, i80-i80.	1.2	0
142	DIPG-31. Prognostic and predictive biomarkers of response in children and young adults with H3K27M-altered diffuse intrinsic pontine glioma: results from a multi-center, interventional clinical trial (PNOC003). Neuro-Oncology, 2022, 24, i25-i25.	1.2	0
143	DIPG-49. International preclinical drug discovery and biomarker program informing an adoptive combinatorial trial for DMG. Neuro-Oncology, 2022, 24, i29-i30.	1.2	0
144	DIPG-47. TSO500ctDNA sequencing reveals oncogenic mutations and copy number variations in the liquid biome of children with diffuse midline glioma. Neuro-Oncology, 2022, 24, i29-i29.	1.2	0